Traditional vs specialty per claimant drug spending Canada 2008-2019

This statistic shows the distribution of annual spending per claimant based on traditional vs. specialty drugs in Canada for selected years from 2008 until 2019. During this time span, the proportion of annual per claimant spending on specialty drugs increased from 15 percent in 2008 to 33 percent in 2019.

Proportion of traditional and specialty drug spending per claimant in Canada from 2008 to 2019*

Characteristic	Speciality	Traditional
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-
-	-	-

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

April 2020

More information

Region

Canada

Survey time period

2008 to 2019

Supplementary notes

* Spending: Total cost of eligible prescription drugs, including the plan member’s portion as well as the plan sponsor’s portion net of any Product Listing Agreement discounts.
Specialty drugs: Medications used to treat chronic, complex conditions such as severe rheumatoid arthritis, multiple sclerosis and cancer. Includes injectable and non-injectable drugs and have one or more of the following qualities: frequent dosing adjustments and intensive clinical monitoring; intensive patient training and compliance assistance; limited distribution; and/or specialized handling or administration.
Traditional drugs: Medications that are easy to self-administer and require less intensive clinical monitoring, such as those used to treat diabetes and high blood pressure
Claimant refers to each person who submits a prescription drug claim, including all dependents who are eligible for coverage.

Citation formats